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Activation of cannabinoid system in anterior cingulate cortex
and orbitofrontal cortex modulates cost-benefit decision making
Abbas Khani & Mojtaba Kermani & Soghra Hesam &
Abbas Haghparast & Enrike G. Argandoña &
Gregor Rainer
Abstract Despite the evidence for altered decision making in
cannabis abusers, the role of the cannabinoid system in
decision-making circuits has not been studied. Here, we ex-
amined the effects of cannabinoid modulation during cost-
benefit decisionmaking in the anterior cingulate cortex (ACC)
and orbitofrontal cortex (OFC), key brain areas involved in
decision making. We trained different groups of rats in a
delay-based and an effort-based form of cost-benefit T-maze
decision-making task. During test days, the rats received local
injections of either vehicle or ACEA, a cannabinoid type-1
receptor (CB1R) agonist in the ACC or OFC. We measured
spontaneous locomotor activity following the same treatments
and characterized CB1Rs localization on different neuronal
populations within these regions using immunohistochemis-
try. We showed that CB1R activation in the ACC impaired
decision making such that rats were less willing to invest
physical effort to gain high reward. Similarly, CB1R activa-
tion in the OFC induced impulsive pattern of choice such that
rats preferred small immediate rewards to large delayed re-
wards. Control tasks ensured that the effects were specific for
differential cost-benefit tasks. Furthermore, we characterized
widespread colocalizations of CB1Rs on GABAergic axonal
ends but few colocalizations on glutamatergic, dopaminergic,
and serotonergic neuronal ends. These results provide first
direct evidence that the cannabinoid system plays a critical
role in regulating cost-benefit decision making in the ACC
and OFC and implicate cannabinoid modulation of synaptic
ends of predominantly interneurons and to a lesser degree
other neuronal populations in these two frontal regions.
Keywords Anterior cingulate cortex . Cannabinoid .
Decisionmaking . Orbitofrontal cortex . T-maze
Introduction
Cannabinoids are the main active ingredients of marijuana, an
illicit drug in many countries that is widely used as a recrea-
tional substance due to its psychoactive effects. There is
considerable evidence implicating the use of various cannabis
derivatives in altered cognition and decision making, includ-
ing risk taking behavior, irrational (or excessive) gambling, as
well as impulsive and apathetic patterns of choice. This evi-
dence comes mainly from human studies (Dougherty et al.
2013; Grant et al. 2012; Hermann et al. 2009; Lane et al. 2005;
Moreno et al. 2012; Solowij et al. 2012; Whitlow et al. 2004)
and related work in animals (Boomhower et al. 2013; Egerton
et al. 2006; Egerton et al. 2005; Mishima et al. 2002) that
largely concurs with the results of the human studies. The role
of cannabinoid signaling in decision-making pathways and
the involvement of cannabinoid receptors in frontal cortical
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circuits of decision making have not received much attention
to date.
Endocannabinoids have emerged as fundamental mod-
ulators of synaptic function regulating a wide range of
brain functions including feeding behavior (Engeli 2012),
memory (Hampson et al. 2011; Jacob et al. 2012), stress
responses (Ganon-Elazar and Akirav 2009), motor control
(Dubreucq et al. 2013), and pain processing (Lee et al.
2013; Martin et al. 1999). Cannabinoids predominantly
exert their modulatory effects in a retrograde manner by
binding to cannabinoid receptors on presynaptic terminals
(Castillo et al. 2012; Kano et al. 2009). Cannabinoid type-
1 receptors (CB1Rs) are highly abundant in many brain
regions including frontal areas and are thought to mediate
most of the brain cannabinoid system functions (Egertova
and Elphick 2000; Kano et al. 2009; Katona and Freund
2008; Tsou et al. 1998). CB1Rs are densely distributed in
cerebral cortex with the highest abundance in the cingu-
late cortex and association cortical regions of the frontal
l ob e (Eggan and Lew i s 2007 ; Ma i l l e ux and
Vanderhaeghen 1992; Svizenska et al. 2008). For exam-
ple, Eggan and Lewis demonstrated a higher density of
CB1Rs in the cingulate cortex and associative prefrontal
regions compared to primary sensory and motor cortices
(2007). The anterior cingulate cortex (ACC) and
orbitofrontal cortex (OFC), two key brain regions with
high prevalence of CB1Rs (Eggan and Lewis 2007;
Filbey et al. 2010), play a cardinal role in information
processing during decision-making tasks (Bechara et al.
2000; Kennerley et al. 2011). It has been shown that these
two brain regions have partially dissociable roles in sev-
eral dimensions of decision making (Khani 2014; Lee
et al. 2007; Rushworth et al. 2007) which include the
evaluation of the expected benefits as well as costs asso-
ciated with each potential choice of action during a deci-
sion. In decision-making paradigms, costs typically take
the form of delay costs, corresponding to a time delay,
during which the subject has to wait for an expected
benefit, or effort costs, where subject must expend phys-
ical effort to gain access to an expected benefit. A recent
lesion study has shown that, indeed, the ACC and OFC
are involved in the processing of distinct decision costs
during decision making (Rudebeck et al. 2006). While
ACC-lesioned rats exhibited similar decisions as control
animals for delay costs, they exhibited pronounced defi-
cits during decisions involving effort costs. The converse
was true in the OFC: OFC-lesioned rats were highly
impaired on decisions involving delay costs, but not dif-
ferent from control animals in decisions based on the
effort costs. A human neuroimaging study showed a sim-
ilar double dissociation between OFC and ACC in terms
of processing of delay and effort decision costs (Prevost
et al. 2010).
The role of different neurotransmitters/modulators in mod-
ulating neural circuits of decision making in the frontal lobe
remains poorly understood. We aimed here to explore the
modulatory effects mediated by cannabinoids on effort-
based and delay-based decision making in the ACC and
OFC. To address this, we used microinjections of cannabinoid
agents into the ACC and OFC during both versions of the
cost-benefit decision task. This allowed us to investigate
whether the double dissociation between the ACC and OFC
in the processing of distinct decision costs holds true follow-
ing cannabinoid system activation in these same brain struc-
tures. It is noteworthy that cannabinoid-induced disturbances
in the frontal cortex functions have been described for both
acute as well as chronic cannabinoid administration. The aim
of the current study is to shed light on the acute modulatory
role of the cannabinoid system in these areas during decision
making and long-term changes resulting from chronic canna-
binoid consumption may rely on different mechanisms that
need to be studied separately. In addition to the behavioral
experiments, we characterized the neuronal populations in-
volved using double-immunohistochemistry of the CB1R and
selected neuronal markers. We also performed control exper-
iments to demonstrate that these impairments are indeed cost-
benefit decision-making impairments and are not the result of
memory or locomotor confounds.
Materials and methods
Subjects
A total of 54 male Wistar rats (Pasteur Institute, Iran or
Janvier, Europe) were used as subjects. The rats were 8 weeks
old at their arrival to the animal facility. Rats were housed in
groups of three per cage under standard conditions in a
temperature-controlled room and maintained on a standard
12-h light/dark cycle (lights on at 0700 hours). Water was
available ad libitum. The animals were handled on a daily
basis and food was adjusted for initial body weights of about
90 % of the free feeding weight during the beginning of the
behavioral experiment (270–300 g) and after this a controlled
weight gain of about 6–12 g per week. All animals were naïve
to the current tests and had no prior experience in any behav-
ioral experiment. Main behavioral experiments, histological
analyses and sample preparations for microscopy, and confo-
cal microscopy were carried out at Shahid Beheshti Medical
University, University of Fribourg, and University of the
Basque Country, respectively. All experiments were executed
in compliance with applicable Swiss regulations and the Eu-
ropean Community Council Directive (2010/63/EU), or in
accordance with the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health Publication No. 80–23,
revised 1996) in Iran.
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Apparatus
T-mazes were constructed with parameters adopted from the
study by Denk et al. (2005). The wooden mazes had three
arms each 60 cm long, 10 cm wide, and 40 cm high. The floor
and lower parts of the inner walls of the maze were painted
with a transparent oil-based color to maintain a homogenous
appearance of the maze. Metal food wells, 3 cm in diameter,
were placed at the end of the goal arms 2 cm above the maze
floor. For experiment 1, three-dimensional triangular barriers
made ofmeshwire with different heights (5–30 cm) were used
in the midpoint of the high-reward goal arm to introduce
different levels of physical effort cost in different stages of
training. For experiment 2, four retractable doors were built in
the goal arms of the maze. One door was placed just before the
food well at each arm, 5 cm from the end of the arm and the
other after the entrance into each arm, 12.5 cm from the
entrance point (Fig. 1). These doors were used to delay the
access of the animals to rewards in delay-based decision-
making task. Furthermore, there were grooves at the
beginning of the entrance to each goal arm in both mazes,
where a barrier of 10 cm width and 40 cm height could be
placed on certain trials to force the animal to go to one of the
goal arms (“forced” trials). The maze was placed 1 m above
the room floor and a video camera was mounted at the top to
monitor animal behavior.
Behavioral training
Rats were trained to perform T-maze decision-making tasks
with a differential cost (short vs. long waiting time or low vs.
high effort) and reward (small vs. large reward amount) in the
two arms of the maze. Figure 1C shows the sequence of
training and experimental stages. With some slight differ-
ences, the procedure was adopted from the previous work
(Denk et al. 2005; Rudebeck et al. 2006). Briefly, the rats
were handled and weighed every day during the first week
following their arrival. About 1 week after the beginning of
food scheduling, the animals were habituated to the maze. For
3 days, the animals were allowed to explore the maze for
Fig 1 Schematic illustration of the experimental apparatus. a Effort-
based T-maze decision-making task. The animals could choose between
a low reward and a high-reward arm. However, they had to put in physical
effort to climb a barrier in order to gain a higher reward. bDelay-based T-
maze decision-making task. The animals could choose between an
immediately available small reward and a delayed large reward. c Se-
quence of training and experimental procedures for both tasks. Stages 5,
7, and 9 indicates testing days during the original differential cost tasks
and stages 11 and 13 refer to testing days during control equal cost tasks
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7 min in groups of three with ten food pellets (45 mg food
reinforcement pellets, Formula A/I; P.J. Noyes) in the food
wells in both goal arms.
Experiment 1 Following habituation to the maze, the animals
(experiment 1a: n=10 and experiment 1b: n=8) were random-
ly assigned to receive high reward in the left arm or in the right
arm. For the next 2 days, four pellets were placed in the high-
reward arm (HRA) and two pellets in the low-reward arm
(LRA) for every animal, and the animals were placed individ-
ually in the start arm and were allowed to sample the pellets
from both sides without a barrier in any of the goal arms. The
same procedure was carried out for three additional days, but
instead of one trial per day, the animals completed four trials
per day. Subsequently, animals were allowed to sample food
from only one of the goal arms. They performed two “forced”
trials and ten “choice” trials per day for three further days. At
this stage, the animals had free access to both HRA and LRA
without any barrier on the way. During this phase, the animals
had to choose one of the goal arms and they were removed
from the maze following the consumption of the reward in the
chosen arm well. Once the animals had reached an average
high-reward choice (HRC) of 80 % or more, a barrier of 5 cm
high made of wire mesh was placed in the midpoint of the
HRA to increase physical effort cost of the high reward.
Similarly, after a few days of training in this phase and
exceeding the average HRC of 80 %, the barrier height was
increased in 5 cm steps till the maximum height of 30 cm at
the end of training. The animals needed 2–4 days to complete
each of these phases of the decision training, and a few more
days of training were then conducted to consolidate the task
before animals underwent the surgery for cannula implanta-
tion. One rat from group 1a was not willing to perform the task
and follow the training and was thus excluded from the
experiment.
Experiment 2 A separate group of animals (experiment 2a:
n=10 and experiment 2b: n=8) were used for this experiment.
Following habituation to the maze, animals were randomly
assigned to receive high rewards in the left arm or in the right
arm. For the next 2 days, ten pellets were placed in HRA and
two pellets in the LRA for every animal and the animals were
placed individually in the start arm and were allowed to
sample the pellets from both sides with all four doors in an
open state. The same procedure was carried out for three
additional days, but instead of one trial per day, the animals
completed four trials per day. Subsequently, animals were
allowed to sample food from only one of the goal arms. They
performed two “forced” trials and ten “choice” trials per day
for three further days. At this stage, door B was closed in both
goal arms and once the rat entered a goal arm, door A was
closed and door B was opened and the animal had access to
the chosen food well. During this phase, the animals had to
choose one of the goal arms and they received an immediate
reward in both arms. Once the animals had reached an average
HRC of 80 % or more, a delay of 5 s was introduced to the
HRA. Similarly, after a few days of training in this phase and
exceeding the average HRC of 80 %, the delay was increased
to 10 and then 15 s. One rat was not able to perform the task
and follow the training and was excluded from the experi-
ment. The animals needed 4–6 days to complete each of these
phases of the decision training, and a few more days of
training were then conducted to consolidate the task before
animals underwent the surgery for cannula implantation.
Surgery
After an induction of anesthesia, achieved using a mixture of
ketamine (100 mg/kg) and xylazine (8 mg/kg) intraperitoneal
(i.p.) injection, rats were immobilized in a stereotaxic device
(Stoelting Co., USA). An incisionwas made along the midline
on the head of the rats and the skull was exposed. Stainless
steel, 23 gauge guide cannulae were implanted bilaterally
1 mm above the target locations. The coordinates for target
locations (ACC and OFC) were determined from a rat brain
atlas (Paxinos and Watson 2007) as follows: 1.2 mm anterior
to bregma, 0.8 mm lateral to the midline, and 2 mm ventral to
the skull for ACC and 3.5 mm anterior to bregma, 2.3 mm
lateral to the midline, and 5.4 mm ventral to the skull for OFC.
After securing the guide cannulae in place, dental acrylic
cement (Paladur) was applied to fix the implants. Before
recovery from the anesthesia, the animals received 0.05mg/kg
buprenorphine and baytril (ciprofloxacin). Both drugs were
administered s.c. and buprenorphine was repeated after 12 h.
Removable stylets with the same length as the guide cannulae
were inserted into the guide cannulae and were only removed
during microinjections. Following the surgery, rats were
housed individually, were monitored on a daily basis, and
were allowed to recover from the surgery at least for 10 days
before restarting any behavioral training. For 2 days before the
surgery and during the recovery period, rats had free access to
food and water.
Microinjections and behavioral testing
Experiment 1a Following recovery from the surgery and re-
establishment of the restricted food regime, the animals com-
pleted two “forced decision” trials followed by ten “choice”
trials of the effort-based T-maze decision-making task per day
for 2–3 days, until they reached the presurgery performance
rate. To ensure steady behavior, the training was continued for
10 days. ACC injections were counterbalanced such that
animals first received either potent cannabinoid agonist
(ACEA) or dimethyl-sulfoxide (DMSO; vehicle). During the
test days, after the “forced decision” trials, the animals re-
ceived bilateral microinjection of either ACEA (Tocris
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Bioscience UK, 0.73 μg/side dissolved in DMSO) or vehicle
in the ACC in a counterbalanced manner; the animals that
received local ACEA treatment on the first test day were
subjected to local vehicle treatment and vice versa. The ani-
mals performed the task for 3 days without any manipulation
between test days with microinjections. The dose we used
falls within the dose range of previous studies employing
intracerebral application of high-affinity cannabinoid agonists
including ACEA and CP55940 (Fogaca et al. 2012; Miller
et al. 1998; Moreira et al. 2007; Robbe et al. 2006). All
microinjections were administered in a volume of 0.5 μl per
side over 60 s using a stainless steel needle (30 gauge) which
was directly inserted into the guide cannula, protruding 1 mm
beyond the tip of the cannula. The injector cannula was
connected to a 1-μl Hamilton syringe by polyethylene tubing
(PE-20). The injectors were left in place for 60 s after the
injection to allow diffusion and were then replaced by the
stylets. The behavioral testing was continued after the micro-
injections in exactly the same way as before and the animals’
behavior was recorded. After the microinjection of ACEA and
vehicle, the animals received a microinjection of cannabinoid
antagonist, AM251 (Tocris Bioscience, 5.55 μg /side dis-
solved in DMSO) to study the influence of CB1R inactivation
of the ACC in the effort-based decision-making task. A 3-day
interval of behavior without any manipulation was maintained
for all microinjections.
After the completion of all behavioral testing with micro-
injection in the effort-based decision task, the animals were
trained on a control task in which a similar 30 cm height
barrier was newly introduced also to the LRA, to test possible
involvement of spatial preference or memory in the decisions
of the animals. The training continued for about 10 days to
ensure that the changed rule was well established for the
animals. On the test days, the animals received microinjec-
tions of ACEA and saline in a counterbalanced manner and
behavioral parameters were analyzed as above.
Experiment 1b The experimental procedure and treatment
schedule was performed exactly in the same way as in the
differential effort task in experiment 1a. The only difference
was however, that, the rats in this group had cannulae in the
OFC and received local treatments in the OFC.
Experiment 2a Following recovery from the surgery and re-
establishment of the restricted food regime, the animals com-
pleted two “forced decision” trials followed by ten “choice”
trials of the delay-based T-maze decision-making task per day
for 2–3 days, until they reached the presurgery performance
rate. To ensure steady behavior, the training was continued for
10 days. One rat did not recover and was not able to follow the
task as he did before the surgery and therefore was excluded
from the experiment. During the test days, after the “forced
decision” trials, the animals received bilateral microinjection
of either ACEA (Tocris Bioscience, 0.73 μg /side dissolved in
DMSO) or vehicle in the OFC in a counterbalanced manner;
the animals that received local ACEA treatment on the first
test day were subjected to local vehicle treatment and vice
versa. In this experiment also, the animals performed the task
for 3 days without any manipulation between test days with
microinjections. All microinjections were administered in a
volume of 0.5 μl per side over 60 s using a 1-μl Hamilton
syringe. Sixty seconds after the injection, the injectors were
removed and were replaced by the stylets. The behavioral
testing was continued after the microinjections in the same
way as before and the animals’ behavior was recorded. The
animals performed the task for 3 days without any manipula-
tion between the microinjection days. After the microinjection
of ACEA and vehicle, the animals received a microinjection
of cannabinoid antagonist, AM251 (Tocris Bioscience,
5.55 μg /side dissolved in DMSO) to study the influence of
CB1R inactivation of the OFC in the delay-based decision-
making task. A 3-day interval of behavior (decision task)
without any manipulation was maintained for all
microinjections.
After the completion of all behavioral testing with micro-
injection in the delay-based decision task, the animals were
trained on a control task in which a similar 15 s delay was
newly introduced also to the LRA, to test possible involve-
ment of spatial preference or memory in the decisions of the
animals. The training continued for about 10 days to ensure
that the changed rule was well established for the animals. On
the test days, the animals received microinjections of ACEA
and saline in a counterbalanced manner and behavioral pa-
rameters were analyzed as above.
Experiment 2b Similar to experiment 2a, the rats performed
delay-based decision task. All experimental procedure was
similar to differential delay task in experiment 2a with the
only difference that the rats in this group had cannulae im-
planted in the ACC and received the local microinjections in
the ACC.
Locomotor activity control experiment
The equal cost control experiments were exactly the same as
the test experiments except equating the costs so they control
for all cost-benefit decision-making irrelevant factors such as
memory, locomotor ability, or possible spatial preferences in
the same setting as test experiments. However, it can be
argued that changes in the activity level as a result of canna-
binoid system activation can bias animals’ choice in the
presence of differential costs. A further control experiment
was conducted to measure spontaneous locomotor activity of
the rats’ following cannabinoid system manipulation. Two
separate groups of rats were implanted with cannulae aimed
at the ACC (n=6) or the OFC (n=6). The coordinates and
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surgery procedure were the same as described above. In both
ACC and OFC groups, the animals received microinjections
of ACEA, vehicle, and AM251 in the same counterbalanced
manner as described above and then their activity was record-
ed in an open field. In these experiments also a 3-day interval
of no manipulation between microinjections was applied.
The open field test was used to address the spontaneous
motor activity profile following cannabinoid system manipu-
lation in the ACC and OFC. Ten minutes after microinjection,
rats were placed in the center of an open field measuring
30 cm×30 cm with 30 cm walls and were allowed to freely
move inside the arena for 10 min. The activity was recorded
through a 3CCD camera (Panasonic Inc., Japan) mounted 2 m
above the open field and was analyzed offline using
Ethovision video tracking software (version 3.1, Noldus In-
formation Technology, The Netherlands).
Tissue preparation, immunohistochemistry, and fluorescence
microscopy
A separate group of six naïve male Wistar rats aging 3 months
old were euthanized by i.p. injection of pentobarbital and were
transcardially perfused with a saline 0.9 % solution followed
by a fixative containing 4 % paraformaldehyde (PFA) in
0.1M phosphate-buffered saline solution (PBS).Whole brains
were removed and stored in fresh PFA 4 % solution at 4 °C
overnight and then passaged to a solution of 30 % sucrose in
0.1 M PBS until the tissues sank. The brains were then
coronally cut into 50 μm sections using a freezing microtome
(Leica Biosystems) and serially collected sections were kept
in 0.1 M PBS to be immunohistochemically processed using
the free-floating method. The slices were washed in PBS three
times and then were incubated for 1 h in a PBS solution
containing 5 % bovine serum albumin and 0.5 % TritonX100
to block unspecific reactions. The brain sections were then
incubated for 24 h at room temperature in single primary
antibodies or in a cocktail of two primary antibodies raised
in different species diluted in the blocking solution. Primary
antibodies that we used in our immunohistochemistry (IHC)
experiments are as follows: guinea pig anti-CB1R C-terminus
polyclonal antibody (1:1,000 dilution; Frontier Institute, Ja-
pan), rabbit anti-glial fibrillary acidic protein (GFAP) poly-
clonal antibody (1:300 dilution; DAKO, Denmark), rabbit
anti-vesicular GABA transporter (VGAT) polyclonal antibody
(1:100 dilution; Millipore, MA, USA), rabbit anti-tyrosine
hydroxylase (TH) polyclonal antibody (1:1,000 dilution;
Millipore), rabbit anti-vesicular glutamate transporter type 1
(VGlut1) polyclonal antibody (1:300 dilution; Abcam, UK)
and rabbit anti-serotonin transporter (SERT) polyclonal anti-
body (1:500 dilution; Abcam). Brain slices including the ACC
and OFC were incubated in a blocking PBS solution contain-
ing one of the primary antibodies or a mixture of one of the
every other primary antibody with anti-CB1R antibody. The
following day, the sections were washed again in PBS three
times and were incubated for 2 h in the blocking solution
containing appropriate secondary antibody(ies). Alexa Fluor
568 goat anti-guinea pig IgG (H+L; 1:400 dilution;
Invitrogen, Life Technologies Co., CA, USA) and Alexa
Fluor 488 donkey anti-rabbit IgG (H+L; 1:400 dilution;
Invitrogen, Life Technologies Co.) were the secondary anti-
bodies used against primary antibodies in these experiments.
The sections were then rinsed, mounted in an aqueous mount-
ingmedia on gelatin-coated slides, and cover-slipped. In every
staining run, there were negative controls in which the primary
antibody was omitted. The 3D fluorescence images were
acquired using confocal fluorescence microscopy with a Zeiss
Axio Observer Z1 microscope with an ApoTome.2 (Carl
Zeiss, Germany) attachment and structured illumination tech-
nique. Z serial sections were acquired at the optimal Nyquist
resolution for each objective, i.e., at 0.54 μm with the ×20
objective (0.8 aperture) and at 0.27 μmwith the ×63 objective
(1.4 aperture) (Webb and Dorey 1995). Z projection from
stack to single image, color levels adjustment, scale bar inclu-
sion, and RGB conversion was performed using appropriate
FIJI plug-ins (Schindelin et al. 2012).
Histology
After the completion of all tests, the animals were deeply
anesthetized by i.p. injection of pentobarbital and
transcardially perfused with saline 0.9 % and PFA 4%.Whole
brains were removed and were fixed in PFA 4 % overnight
and then in sucrose 30 % until they sank. The brains were cut
into 50-μm sections in the coronal plane using a freezing
microtome (Leica Biosystems) and underwent Nissl staining.
Injection sites for available histological placements (n=9, 8, 5,
4 for main experiments 1a, 2a and control experiments 1b and
2b respectively) are depicted in Fig. 2.
Results
Effects of cannabinoid system manipulation in ACC
on effort-based decision making
In experiment 1, rats performed a simple cost-benefit T-maze
decision-making task involving effort cost. Two goal arms
differed in the amount of available reward and in the magni-
tude of physical effort the rats incurred to gain rewards. The
animals were extensively trained before surgery and rapidly
established presurgery performance (i.e., high-reward choices
or HRCs) following a recovery from cannulae implantation
surgery. After several days of consistent behavior, the animals
were randomly assigned to receive intra-ACC (experiment 1a)
microinjection of the potent CB1R agonist ACEA, or vehicle
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in a counterbalanced manner. Subsequently, after a 3-day
interval of behavior without any manipulation, all the animals
received a cannabinoid antagonist, AM251. Figure 3 (left
panel) shows the mean percentage of HRCs obtained for
vehicle, AM251, and ACEAmicroinjection groups. A repeat-
ed measures ANOVA showed a main effect of the local ACC
treatment (F2, 16=179.9; p<0.0001) on the performance of the
rats. While vehicle-microinjected rats continued to choose
high-reward/high-effort arm, cannabinoid agonist
microinjected rats exhibited a strong reduction in HRCs,
which was significantly different than vehicle-microinjected
(Bonferroni post hoc analysis, p<0.0001) or cannabinoid
antagonist-microinjected (Bonferroni post hoc analysis,
p<0.0001) rats. Thus, the activation of CB1R in the ACC
shifted the preference of animals from deciding to expend
physical effort to gain higher reward to choosing a small
reward at low physical cost. AM251 microinjection into the
ACC in our experimental setting could not address whether
cannabinoid system inactivation in the ACC has opposite
effects on effort cost processing due to the possible ceiling
effect. This was the basis to exclude AM251 microinjection in
the subsequent control task.
To evaluate whether the reduction in the HRCs as a result
of intra-ACC microinjection of ACEA specifically affects
effort-based decision making, rather than having a more gen-
eral impact on spatial preference or memory, we proceeded to
train the same group of animals on an additional control task.
In this task, the differential rewards were maintained as before
(four vs. two pellets) but the physical effort cost the rats
incurred to gain different-sized rewards was set to the same
value for both sides (30 cm barrier). Fig. 3 (middle panel)
shows mean percentage of the rats’ HRCs in this new “equal
effort” control task. A two-way repeated measures ANOVA
on ACEA and vehicle microinjection results in both tasks
revealed a significant main effect of the treatment (F1, 8=
202.1; p<0.0001) and a significant main effect of the task
(F1, 8=153.6; p<0.0001; “differential effort” vs. “equal effort”
control task) and a significant treatment×task interaction (F1,
8=169.7; p<0.0001). A subsequent Bonferroni post hoc anal-
ysis revealed a significant reduction in the rats’ HRCs with
ACEA compared to vehicle in the original task (p<0.0001)
but not in the “equal effort” control task. Along similar lines,
there was a significant difference in HRCs between the orig-
inal and the “equal effort” control task in the ACEA
(p<0.0001; Bonferroni post hoc test) but not the vehicle
treatment condition.
To assess whether the reduction in the HRCs as a result of
local cannabinoid system activation during effort-based deci-
sion task is specific to the ACC, a separate group of rats
(experiment 1b) were trained and implanted with cannulae
in the OFC. Figure 3 (right panel) shows the HRCs of the rats
following counterbalanced intra-OFC microinjection of can-
nabinoid agonist and vehicle. Cannabinoid agonist or vehicle
injection in the OFC had no effect on the HRCs as confirmed
by a repeatedmeasures ANOVA (p>0.1). A separate two-way
ANOVA with repeated measures in one factor (treatment)
compared the effects of the treatment and microinjection area
and showed a significant main effect of the treatment (F1, 15=
151.3; p<0.0001), a significant main effect of brain area (F1,
15=75.2; p<0.0001) and a significant interaction (F1, 15=
116.5; p<0.0001). Taken together, the behavioral changes in
effort-based decision making were specific for the ACC but
not OFC cannabinoid activation and these effects were spe-
cific to the original decision task with differential efforts, and
were not observed during a control task with equal effort
costs, ruling out reward memory or spatial preference
confounds.
Effects of cannabinoid system manipulation in OFC
on delay-based decision making
In experiment 2, rats performed a cost-benefit T-maze
decision-making task involving delay cost. As in experiment
1, the two goal arms were different in the amount of available
reward and the magnitude of the cost the rats incurred to gain
Fig 2 Anatomical reconstruction approximate bilateral microinjection
sites in a the ACC (n=9) and b the OFC (n=8). Each “•” or “•” symbol
represents an injection site for an individual animal that was used in the
main experiments or area control experiments, respectively. The distance
of every coronal plane anterior to bregma is denoted on the right side of
the reconstruction schematics. Coronal Nissl-stained sections showing
cannula tracks and injection sites, marked with an “*” symbol in c the
ACC and d the OFC
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these rewards. However, while in experiment 1, the costs were
in terms of physical effort, in experiment 2, the rats based their
decision on different delay costs to achieve different-sized
rewards. Similar to experiment 1, the animals established high
ratio of HRCs following a postsurgery recovery and exhibited
a consistent behavior for several days. Subsequently, the rats
were randomly assigned to receive a local administration of
either ACEA or vehicle in the OFC (experiment 2a) in a
counterbalanced manner. After a 3-day interval of behavior
without any manipulation, all the animals received a cannabi-
noid antagonist, AM251. The mean percentages of HRCs in
delay-based decision task in vehicle, AM251, and ACEA
groups are displayed in Fig. 4 (left panel). A repeated mea-
sures ANOVA showed a significant main effect of the local
OFC treatment (F2, 14=2,076; p<0.0001). Intra-OFC micro-
injection of cannabinoid agonist led to a drastic decline in the
preference of the rats for delayed large rewards being signif-
icantly different than vehicle-microinjected (Bonferroni post
hoc test, p<0.0001) or cannabinoid antagonist-microinjected
(Bonferroni post hoc test, p<0.0001) rats. Thus, as a result of
CB1R activation in the OFC, the rats exhibited an impulsive
pattern of decision making switching from deciding to wait to
gain a large reward to choosing to receive small but immediate
reward. Similar to the effort-based decision task, the prefer-
ence of the rats to high-cost/high-reward choice following
AM251 microinjection into the OFC was not different than
vehicle treatment, which we attribute to a ceiling effect
resulting from the high HRC percentage in the control
condition.
The same group of rats was subsequently trained on a
second task in which the decision was simply based on dif-
ferential reward but equal cost by introducing an equal 15-s
delay for the LRA. Rats rapidly learned the new task. Intra-
OFC microinjection of vehicle or ACEA had no effect on the
mean percentages of HRCs, as shown in Fig. 4 (middle panel).
A two-way repeated measures ANOVA revealed a significant
main effect of the treatment (F1, 7=2,767; p<0.0001) and a
significant main effect of the task (F1, 7=794.3; p<0.0001;
“differential delay” vs. “equal delay” control task) and a
significant treatment by task interaction (F1, 7=1,270;
p<0.0001). A subsequent Bonferroni post hoc analysis re-
vealed a significant reduction in the rats’ HRCs with ACEA
compared to vehicle in the original task (p<0.0001) but not in
the “equal delay” control task. Along similar lines, there was a
significant difference in HRCs between the original and the
“equal delay” control task in the ACEA (p<0.0001;
Bonferroni post hoc test) but not the vehicle treatment
condition.
A separate group of rats (experiment 2b), trained and
implanted with cannulae in the ACC, was then used to test
whether the cannabinoid agonist induced decline in the HRCs
during delay-based decision task is specific for the OFC. As
Fig 3 CB1R Agonist application in ACC increases effort averseness
during decisionmaking.Mean percentage of high-reward choices (HRCs,
±SEM) on the test days, where rats received different local treatments in
the ACC (left and middle panel) and OFC (right panel) and during 3 days
preceding the test days without any manipulation. The left panel shows
the performance on the original differential effort decision task. The
middle panel shows the performance on a control task in which the same
group of rats had to expend an equal amount of physical effort for both
choice options. The CB1R antagonist was not tested in the equal effort
task. The right panel shows the performance on the original differential
effort task in a separate group of rats receiving local treatments in the
OFC. inj. day: injection day (i.e., test day)
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shown in Fig. 4 (right panel), cannabinoid agonist or vehicle
microinjection in the ACC had no effect on the HRCs
(p>0.1). A two-way ANOVAwith repeated measures in one
factor (treatment) compared the effects of the treatment and
injection area on HRCs during delay-based decision task and
showed a significant main effect of the treatment (F1, 14=
511.6; p<0.0001), a significant main effect of area (F1, 14=
249.1; p<0.0001), and a significant interaction (F1, 14=416.6;
p<0.0001). This demonstrates that the behavioral changes in
delay-based decision making were specific for cannabinoid
receptor 1 activation in the OFC but not the ACC and that
these effects were not the result of reward memory or spatial
preference biases confounds.
Effects of cannabinoid systemmanipulation in ACC and OFC
on locomotor activity
A potential concern is that the changes in decision patterns
following microinjection of CB1R agonist into the ACC and
OFC can result from the changes in locomotor activity, such
that cannabinoid system activation in ACC and OFC might
lead to general hypoactivity and hyperactivity, respectively,
which in turn makes rats to appear to choose apathetically or
impulsively. To rule out this potentially confounding factor,
we conducted a control experiment measuring spontaneous
locomotor activity. Following microinjection of vehicle,
AM251, or ACEA, rats were placed in an open field and were
allowed to explore for 10 min. The open-field task was con-
ducted to measure general activity levels of the rats as a
function of manipulation of cannabinoid system in the ACC
or OFC. The profile of spontaneous locomotor activity fol-
lowing different treatments in the two brain areas was highly
similar, suggesting that locomotor activity per se was largely
unaffected by cannabinoid system manipulations in the OFC
and ACC, as shown in Fig. 5. This was confirmed by two
separate two-way repeated measures ANOVA for each brain
region with treatment condition and time bin as factors
(p>0.1).
Distribution and localization of CB1Rs in the ACC and OFC
It is well established that CB1Rs are localized at GABAergic
axonal ends in many brain regions (Bodor et al. 2005;
Kawamura et al. 2006; Matyas et al. 2006) including PFC
(Chiu et al. 2010). There are also reports demonstrating
CB1Rs localization on glutamatergic axonal ends (Domenici
et al. 2006; Kawamura et al. 2006; Reguero et al. 2011) and on
astrocytes (Navarrete and Araque 2008) in various brain re-
gions. We thus examined the pattern of distribution of CB1
receptors and colocalization of these receptors with major
neuronal populations including GABAergic, glutamatergic,
dopaminergic, and serotoninergic neurons and astrocytes in
the ACC and OFC. In both ACC and OFC, there was an
intense staining of CB1 receptors in fibrous, apparently woven
Fig 4 CB1R application in the OFC increases delay averseness during
decision making. Mean percentage of HRCs (±SEM) of the rats in the
differential delay decision task (left panel) and a control task using equal
delays (middle panel). On the test days rats received local administration
of different treatments in the OFC; decision performance is also shown
for the three preceding days without any pharmacological manipulation.
The right panel shows performance of a separate group of rats in
differential delay task. These rats received local treatments in the ACC.
inj. day: injection day (i.e., test day)
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forms with almost no distinguishable staining on cell bodies.
Figures 6 and 7 show the distribution and colocalization
patterns of CB1Rs in the ACC and OFC, respectively. In both
regions, there was widespread colocalization of CB1Rs with
GABAergic axonal ends but only relatively few
colocalizations were apparent with dopaminergic, serotoner-
gic, and glutamatergic axons. We did not observe any
colocalization with astrocytes in either area.
Discussion
Our results demonstrate profound effects of cannabinoid sys-
tem activation on frontal brain circuits of decision making.
Cannabinoid agonist application modified decision behavior,
such that animals tended to make suboptimal decisions by
avoiding decision costs. In rats performing an effort-based
decision task, animals nearly always choose to expend addi-
tional physical effort to obtain a high reward. Microinjection
of the potent CB1R agonist into the ACC, but not the OFC, in
an effort-based decision task led to a large decrease in HRCs.
Similarly, microinjection of a CB1R agonist into the OFC, but
not the ACC, in rats performing a delay-based decision task
dramatically increased choice of a low but immediately avail-
able reward. This shows a double dissociable pattern of can-
nabinoid effects in the ACC and OFC during effort-based and
delay-based decision making, respectively. In the absence of a
need to integrate costs and benefits during decision making,
rats chose high-reward arms in both tasks irrespective of
cannabinoid system activation. An additional, control experi-
ment showed that the spontaneous locomotor activity was not
affected by any of the treatments, suggesting that simple
motor hypo- or hyperactivity cannot account for the observed
changes in decision-making behavior. The cannabinoid sys-
tem manipulations we performed produced decline in rats
HRCs that were similar in size to those produced by lesions
in the ACC and OFC (Rudebeck et al. 2006). This suggests
that local cannabinoid system activation may play a crucial
role in modifying ACC and OFC decision circuits.
The involvement of the ACC in several dimensions of
reinforcement-guided decision making is generally well ac-
knowledged (Rushworth et al. 2007). Lesion and single neu-
ron studies have shown that the ACC plays a critical role in
decisions that require putting in a certain amount of effort to
gain a better reward (Kennerley et al. 2011; Rudebeck et al.
2006). Similarly, several lines of evidence have shown that
while the OFC is also a critical region in decision making, it
has a dissociable role than the ACC in many respects includ-
ing cost processing, i.e., delay costs in the OFC vs. effort costs
in the ACC (Rushworth et al. 2007). The ACC and OFC have
connections with several other brain regions including
basolateral amygdala (BLA) and nucleus accumbens (NAc)
(Rushworth et al. 2007) and the input from the ACC and OFC
to NAc is integrated with input from other regions (Grace
2000; Grace et al. 2007). Both BLA and NAc are involved in
the processing of cost-benefit decision making (Rushworth
et al. 2007). Our results provide the first direct evidence
linking the cannabinoid system to frontal cortical areas during
cost-benefit decision making: In the ACC, cannabinoid
Fig 5 Spontaneous locomotor activity is unaffected by cannabinoid treatments spontaneous locomotor activity during exploration (mean±SEM)
following different treatments in a the ACC and b the OFC during 1-min time intervals for a 10-min period measured in an open field
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activation biases rats’ decisions from putting in physical effort
to attain a higher reward to preferring a small reward at a lower
physical effort cost and in the OFC it shifts rats’ decisions
away from waiting for a large reward toward an immediately
available small reward. Previous work has shown that the
effects of cannabinoids on impulsive decision making have
been complex and controversial. Some studies demonstrated
increased impulsive choice (Hernandez et al. 2014; Loflin
et al. 2014) while others showed unaffected or decreased
impulsive choice following cannabinoid administration
(McDonald et al. 2003; Pattij et al. 2007; Wiskerke et al.
2011). It has also been suggested that genetic factors influence
the effects of cannabinoids on impulsive decision making
(Boomhower et al. 2013) and polymorphisms in CB1R gene
is involved in differential trait impulsivity (Ehlers et al. 2007).
On effort-based decision making, one study (Sink et al. 2008)
showed that CB1R blockade decreased the rats willingness to
press a lever to acquire preferred food and another study
suggested that coadministration of a cannabinoid agonist with
“ecstasy” did not change deficits during effort-based decision
making induced by the administration of “ecstasy” alone
(Schulz et al. 2013). While these studies implicate cannabi-
noid system in the processing of cost-benefit decision making,
they have generally used systemic administration of cannabi-
noid agents. It follows that the net behavioral effect is the
result of cannabinoid action in several brain regions including
not only the ACC and OFC but also the VTA, nucleus ac-
cumbens, and other brain regions expressing CB1Rs. By
contrast, our study employed local administration, allowing
us to clarify specifically the role of cannabinoid action in the
ACC and OFC during decision making. Taken together, our
findings suggest that the cannabinoid system may have oppo-
site effects on different components of the neural circuitry
underlying decision making.
Among neurotransmitter systems, the involvement of do-
pamine (DA) system in effort-based decision making has been
well established, particularly for the mesolimbic dopaminer-
gic projection system that innervates the NAc (Hauber and
Sommer 2009; Mai et al. 2012; Salamone et al. 1994). The
involvement of the mesocortical dopaminergic pathway
projecting to the ACC in decision making is less clear and
remains a subject of debate. For example, while one study has
failed to find evidence for a role of dopaminergic projections
from the ventral tegmental area (VTA) to the ACC in effort-
based decision making (Walton et al. 2005), other authors
have demonstrated that blockade or downregulation of
Fig 6 CB1R distribution and
colocalization in ACC
distribution of CB1 receptors and
VGAT, VGlut1, SERT positive
terminals and TH positive
neurons and GFAP positive
astrocytes in the ACC. Coronal
50 μm sections were
immunostained for CB1R in red
and for all other markers in green.
a There is a dense CB1R
expression in the ACC (b) No
CB1R localization was found on
GFAP positive astrocytes. Only
few terminals show CB1R
colocalization with (c) SERT or
(d) TH positive axons and are
marked with white arrowheads. e
In contrast, a high rate of CB1R
colocalization with VGATwas
observed. Arrowheads show only
some of the colocalizations. Apart
from some evident colocalization
in axosomatic synapses to
pyramidal neurons, whose bodies
are well delimitated, some of the
colocalizations are not related to
pyramidal cell bodies. f Only few
CB1R colocalizations were found
with VGlut1 positive terminals.
Magnifications: ×20 for a, ×63 for
b–f. Scale bars: a, 50 μm; b–f,
10 μm
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dopaminergic neurotransmission in the ACC makes animals
effort aversive during decision making (Schweimer and
Hauber 2005; 2006). As the latter authors discussed, the
differences in the level of DA depletion may largely account
for this discrepancy between results. A substantial DA deple-
tion or blockade of D1 receptors in the ACC is necessary to
impair effort-based decision making. It has also been demon-
strated that DA system in the OFC plays a role in delay-based
decision making (Zeeb et al. 2010). Blockade of dopamine
receptors in the OFC decreased the number of large delayed
reward choices. In our study, we have demonstrated that there
are CB1R colocalizations on DA neurons in the ACC
(Fig. 6d) and OFC (Fig. 7d). Although these colocalizations
were overall relatively infrequent, they may be present on a
notable proportion of DA afferents, since these are relatively
dispersed. This suggests that the CB1R-related cost averse-
ness during decision making may at least in part be mediated
by cannabinoid suppression of DA neurotransmission, al-
though the overall relatively weak colocalization suggests that
this is probably not the main mechanism of cannabinoid
influence on decision making in the ACC. Our IHC experi-
ments have also demonstrated a similar sparse pattern of
CB1R colocalizations on serotonergic neuronal ends. To our
knowledge, serotonergic neurotransmission is not implicated
in effort-based decision making while the involvement of
serotonergic system in the delay-based decision making is
well established (Denk et al. 2005; Hadamitzky et al. 2009).
This suggests that modulation of serotonergic projections to
the OFCmight partly contribute to cannabinoid-induced delay
averseness during delay-based decision making.
Of the neuronal populations tested, GABAergic axonal
ends exhibited the strongest colocalization with CB1Rs in
our immunohistofluorescence experiments. This observation
is in agreement with the notion that predominant effects of
CB1Rs activation in the prefrontal cortex in adulthood are
mediated through the regulation of inhibitory neurotransmis-
sion (McLaughlin et al. 2014). Widespread overlapping of
CB1Rs and GABAergic nerve endings suggests a key role
for endocannabinoids in fine tuning of interneuron activity,
which in turn regulates the net output of the ACC and OFC
through direct and indirect synaptic interaction with cortical
glutamatergic pyramidal cells. The ACC sends glutamatergic
output projections to several cortical areas including motor
and somatosensory cortices, as well as subcortical structures
including the NAc and the VTA (Sesack et al. 1989; Uylings
and van Eden 1990). It has been proposed that these latter
Fig 7 CB1R distribution and
colocalization in OFC Confocal
images showing (a) distribution
of CB1 receptors (red) and double
immunofluorescence for CB1R
with (b) GFAP positive
astrocytes, (c) SERT positive
terminals, and (d) TH positive
neurons, (e) VGAT, and (f)
VGlut1 positive terminals. CB1R
is immunostained in red and all
other markers in green. Double
confocal microscopy show few
CB1R colocalization with SERT-
positive terminals, TH positive
neurons, and VGlut1 positive ter-
minals but no colocalization with
GFAP positive astrocytes and
considerable colocalizations with
VGAT.Magnifications: ×20 for a,
×63 for b–f. Scale bars: a, 50μm;
b–f, 10 μm
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projections may be crucial for mediating the regulatory func-
tion of the ACC during effort-based decision making (Walton
et al. 2006). In addition to these areas, the OFC sends output
projections to the serotonergic neurons in the dorsal raphe
nucleus (Cavada et al. 2000; Roberts 2011; Vazquez-Borsetti
et al. 2009) also, which suggests that the OFC may contribute
to the regulation of serotonergic drive in the brain. Consider-
ing that interneurons exert a direct inhibitory influence on
pyramidal neurons, the cannabinoid-induced suppression of
presynaptic GABA release is expected to cause an increased
pyramidal cell activity. This enhancement of ACC and OFC
pyramidal cell activity should in turn lead to increased gluta-
mate release in their target structures. Such an enhancement is
in clear contradiction to the behavioral consequences of ACC
and OFC lesions: Cannabinoid activation in the ACC and
OFC and lesions of these areas (Rudebeck et al. 2006) induce
similar deficits in effort-based and delay-based decision mak-
ing, respectively. However, according to this mechanism, the
target areas will receive a strengthened input from the ACC
and OFC following local cannabinoid activation whereas the
target areas are deprived from the ACC and OFC input fol-
lowing a lesion in the respective area. This apparent contra-
diction can be explained at least in three different ways. First,
it has been shown that interneurons, particularly in the ACC,
synchronize through gap junctions (Chang and Shyu 2014)
and are responsible for the generation of oscillations in differ-
ent frequencies (Whittington and Traub 2003). It is possible
that despite the strengthened output activity, disruption of
synchronized activity and oscillations necessary for optimal
decision making might account for suboptimal decision mak-
ing following cannabinoid system activation in the ACC and
OFC. Second, cannabinoid system activation can lead to
overactivation-induced disruption of frontal cortex function
(Baiardi et al. 2007). Third, the interneurons might exert a
more sophisticated control on the principal neurons output
through a variety of synapses rather than a simply direct
inhibition of principal neurons. Recently, there have been
several studies demonstrating the importance of interneuron-
interneuron interactions in the processing of cortical functions
(Jiang et al. 2013; Pfeffer et al. 2013; Pi et al. 2013; Xu et al.
2013). These interactions, which consist of inhibition of in-
hibitory neurons, can lead to disinhibition of pyramidal cell
activity by decreasing the net inhibitory drive on these neu-
rons. Functional anatomical data indicates that interneurons
frequently exhibit synaptic contacts with other interneurons in
the mouse ACC (Wu et al. 2009), suggesting that neural
circuits for disinhibition are present in this structure. If indeed
the ACC and OFC cannabinoid effects on decision making
Fig 8 Schema of cannabinoid modulatory effects on frontal cortical
circuits. A simplified schematic representation of neuronal circuitry in
the ACC andOFC illustrating possible synapses that can bemodulated by
cannabinoids. Disinhibitory and inhibitory GABAergic interneurons are
shown in orange and blue, respectively. Excitatory axonal ends are
shown with small circles and inhibitory synaptic ends with a
perpendicular line. Presynaptic CB1Rs are shown as small triangles.
The color of the triangles represent the net effect of CB1R activation on
the glutamatergic output with dark blue and red triangles signifying net
inhibitory and facilitatory influence on the (subpopulation of) output
pyramidal neurons. The electrical synapse between two interneurons is
also depicted, since gap junctions between fast spiking interneurons play
an important role in the generation of oscillations in various frequencies
which might be modulated or disrupted by cannabinoid modulation. Note
that synaptic ends of dopaminergic neurons are mostly excitatory as
depicted. They can however also exert an inhibitory influence on some
synapses, an effect that is dependent on the relative densities of D1 and
D2-like receptors. Pyr; Pyramidal neuron
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involve disinhibitory mechanisms, it follows that the CB1R
receptors would have to be localized predominately in
GABAergic presynapses that contact other GABAergic, and
not glutamatergic, cortical neurons. This is the case because
depending on interneuron connectivity, CB1R-mediated sup-
pression of GABA release may have the opposing effects: net
enhancement of pyramidal neuron output when an interneuron
to pyramidal neuron synapse is modulated or net inhibition of
pyramidal neuron output when an interneuron to interneuron
synapse is modulated. Figure 8 summarizes the possible
mechanisms by which cannabinoids might modulate activity
within the ACC and OFC. It has to be noted that the deficits
induced by injection of cannabinoid agonist were in some
cases even more severe than those induced by the lesion of
the respective area. This might be explained by the fact that
the lesion shuts down the functional connectivity of the area
while in the current study the functional connectivity remains
intact and can exert stronger influence on behavior using one
or more of the possible mechanisms described above.
Finally, we observed sporadic colocalizations of CB1Rs on
glutamatergic axonal ends in the ACC and OFC, suggesting
that direct effects of cannabinoids on glutamatergic neurons
may play a minor role in mediating behavioral deficits during
effort-based and delay-based decision making. However, we
cannot rule out the importance of the cannabinoid modulation
of the ACC excitatory input during effort-based decision task.
Indeed, CB1R-dependent impairments in locomotor, temper-
ature homeostasis, and nociceptive functions have been
shown to involve mostly glutamatergic and not GABAergic
neural populations (Monory et al. 2007).
In summary, our experiments suggest that cannabinoid
system is a major regulator of synaptic transmission in the
ACC and OFC and plays a critical role in the balanced
processing of effort and delay costs in cost-benefit decision
making. A number of studies showed high CB1R binding and
elevated levels of endogenous cannabinoids in schizophrenia
(Zavitsanou et al. 2004) in the ACC and in alcohol depen-
dence (Neumeister et al. 2012) in the ACC and OFC, disor-
ders in which executive function and decision making have
been compromised which implicates cannabinoid system ab-
normalities in the pathology of these disorders. Future work
should determine further characteristics, including but not
limited to dose–response profile, of endocannabinoid regula-
tion of decision-making processes with possible clinical im-
plications, and therapeutic potential of manipulating cannabi-
noid system function in a range of psychiatric disorders with
impairments in decision making.
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